Recent fabrications and applications of cardiac patch in myocardial infarction treatment

Myocardial infarction caused by coronary artery obstruction results in the loss of heart muscle, which is subsequently replaced by scar tissue with limited therapeutic options. Cardiac patch based therapy has emerged as a promising strategy for the treatment of severe myocardial infarction. They are designed to be attached to the surface of the heart, that is, they are meant to patch the injured heart, thus restoring the damaged or failing myocardium locally through mechanical and regeneration support. The engineered three-dimension cardiac patch is composed of biomaterial scaffolds with/without cells or inducible factors, which is typically manufactured by decellularize extracellular matrix, electrospinning, three-dimension printing, hydrogels, or by stacking cell sheets. In this review, we outline the latest advances of the construction methods and beneficial effects of cardiac patches used in animal and clinical treatment of cardiovascular diseases, especially in myocardial infarction. We discuss the cell souring of cell-based patches, the types of biomolecules for cell-free patches, and their engineering methods. In addition, the method of implanting the cardiac patch to the injured heart is also described. Finally, we briefly outlook the future challenges and probable solutions in this area.

Automated summary

Cardiac patches have emerged as a promising strategy for treating severe myocardial infarction by restoring damaged heart muscle through mechanical and regeneration support. These patches are typically composed of biomaterial scaffolds with or without cells and inducible factors, and are manufactured using various engineering techniques such as decellularized extracellular matrix, electrospinning, three-dimensional printing, hydrogels, or stacked cell sheets. The review outlines the latest advances in construction methods and beneficial effects of cardiac patches in animal and clinical treatment of cardiovascular diseases, particularly in myocardial infarction, discussing cell sourcing for cell-based patches, biomolecules for cell-free patches, engineering methods, and the implantation process. Future challenges and potential solutions in this area are also briefly discussed.